Using data from the BreastSurgANZ Quality Audit database between 2001 and 2014, patients who declined recommended treatment for breast cancer had poorer 5‐ and 10‐year relapse‐free survival compared to those who received them. These data may help clinicians assist patients with breast cancer in...
Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer. 2008;44:992–9.Jones AP, Haynes R, Sauerzapf V, Crawford SM, Zhao H, Forman D. Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate ...
There is some evidence that cucurbitacin E can improve treatment of multidrug-resistant breast cancer cells by targetingEGFRand silencing its downstream signaling paths. In fact, cucurbitacin E has been reported to increase the treatment effects of Adriamycin in ovarian cancer cells. ...
Celery flavone apigenin has been found to induce apoptosis across a variety of breast cancer cell lines. For example, apigenin has been shown to exhibit potent growth-inhibitory effects inHER2+breast cancer cells. Exposure of HER2+ breast cancer cells to apigenin results in induction of apoptosis ...
It would be used for postmenopausal women who haven't previously been treated with hormonal therapy such as aromatase inhibitors or tamoxifen. Of the 32,000postmenopausal womendiagnosed with breast cancer each year in England, it's estimated that up to 1,200 would be eligible for treatment with...
Last month, the KBCS released the 10th Korean Breast Cancer Treatment Recommendations, which includes the latest treatment guidelines for breast cancer, including adjuvant therapy after lumpectomy. In the revised recommendation, Lynparza has been updated to the Level of Evidence 1, Class of Recommenda...
physical function. This is particularly true for women with breast cancer who receive multi-modality treatment over an extended period of time," said Cohen. "With our studies, we think that we could help ameliorate the treatment-related side effects that accumulate in cancer patients over time."...
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have...
He had a [stem cell] transplant and multiple lines of treatment. He was also previously in a City of Hope trial for a bispecific antibody, and then we were talking about [selinexor] and then he didn’t do well [on the trial], so I didn’t use it. ANDREW PHAM, MD: I used it ...
patients largely expressed major concerns about the high out-of-pocket costs related to cancer treatment. One patient expressed, “I would get receipts from (insurer) explaining what the bills were and how they took care of them and the amounts of the bills and what they were for. The bill...